References
1. Stevens W, Shih T, Incerti D, Ton TGN, Lee HC, Peneva D, Macones GA,
Sibai BM, Jena AB. Short-term costs of preeclampsia to the United States
health care system. Am J Obstet Gynecol 2017; 217 :
237-248.e216.
2. Shennan AH, Green M, Chappell LC. Maternal deaths in the UK:
pre-eclampsia deaths are avoidable. Lancet 2017; 389 :
582-584.
3. Steer P. The epidemiology of preterm labour. BJOG 2005;112 Suppl 1 : 1-3.
4. Brown MA, Magee LA, Kenny LC, Karumanchi SA, McCarthy FP, Saito S,
Hall DR, Warren CE, Adoyi G, Ishaku S, (ISSHP) ISftSoHiP. Hypertensive
Disorders of Pregnancy: ISSHP Classification, Diagnosis, and Management
Recommendations for International Practice. Hypertension 2018;72 : 24-43.
5. Excellence NIfC. Hypertension in Pregnancy: diagnosis and
management. . https://www.nice.org.uk/guidance/ng133, 2019.
6. Zhang J, Klebanoff MA, Roberts JM. Prediction of adverse outcomes by
common definitions of hypertension in pregnancy. Obstet Gynecol2001; 97 : 261-267.
7. Milne F, Redman C, Walker J, Baker P, Black R, Blincowe J, Cooper C,
Fletcher G, Jokinen M, Moran PA, Nelson-Piercy C, Robson S, Shennan A,
Tuffnell A, Waugh J, Group PI. Assessing the onset of pre-eclampsia in
the hospital day unit: summary of the pre-eclampsia guideline (PRECOG
II). BMJ 2009; 339 : b3129.
8. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman
EF, Thadhani R, Sachs BP, Epstein FH, Sibai BM, Sukhatme VP, Karumanchi
SA. Circulating angiogenic factors and the risk of preeclampsia. N
Engl J Med 2004; 350 : 672-683.
9. Saffer C, Olson G, Boggess KA, Beyerlein R, Eubank C, Sibai BM, Group
NS. Determination of placental growth factor (PlGF) levels in healthy
pregnant women without signs or symptoms of preeclampsia.Pregnancy Hypertens 2013; 3 : 124-132.
10. Chaiworapongsa T, Romero R, Kim YM, Kim GJ, Kim MR, Espinoza J,
Bujold E, Gonçalves L, Gomez R, Edwin S, Mazor M. Plasma soluble
vascular endothelial growth factor receptor-1 concentration is elevated
prior to the clinical diagnosis of pre-eclampsia. J Matern Fetal
Neonatal Med 2005; 17 : 3-18.
11. Chau K, Hennessy A, Makris A. Placental growth factor and
pre-eclampsia. J Hum Hypertens 2017; 31 : 782-786.
12. Chappell LC, Duckworth S, Seed PT, Griffin M, Myers J, Mackillop L,
Simpson N, Waugh J, Anumba D, Kenny LC, Redman CW, Shennan AH.
Diagnostic accuracy of placental growth factor in women with suspected
preeclampsia: a prospective multicenter study. Circulation 2013;128 : 2121-2131.
13. Excellence NIfC. PlGF-based testing to help diagnose suspected
pre-eclampsia (Triage PlGF test, Elecysys immunoassay sFlt-1/PlGF ratio,
DELFIA Xpress PlGF 1-2-3 test, and BRAHMS sFlt-1 Kryptor/BRAHMS PlGF
plus Kryptor PE ratio) https://www.nice.org.uk/guidance/dg23,
2016.
14. Barton JR, Woelkers DA, Newman RB, Combs CA, How HY, Boggess KA,
Martin JN, Kupfer K, Sibai BM, Trial PPTbRA. Placental growth factor
predicts time to delivery in women with signs or symptoms of early
preterm preeclampsia: a prospective multicenter study. Am J Obstet
Gynecol 2019.
15. Parchem JG, Brock CO, Chen HY, Kalluri R, Barton JR, Sibai BM,
Investigators PTbRATP. Placental Growth Factor and the Risk of Adverse
Neonatal and Maternal Outcomes. Obstet Gynecol 2020.
16. Duhig KE, Myers J, Seed PT, Sparkes J, Lowe J, Hunter RM, Shennan
AH, Chappell LC, group Pt. Placental growth factor testing to assess
women with suspected pre-eclampsia: a multicentre, pragmatic,
stepped-wedge cluster-randomised controlled trial. Lancet 2019;393 : 1807-1818.
17. Duckworth S, Chappell LC, Seed PT, Mackillop L, Shennan AH, Hunter
R. Placental Growth Factor (PlGF) in Women with Suspected Pre-Eclampsia
Prior to 35 Weeks’ Gestation: A Budget Impact Analysis. PLoS One2016; 11 : e0164276.
18. Frampton GK, Jones J, Rose M, Payne L. Placental growth factor
(alone or in combination with soluble fms-like tyrosine kinase 1) as an
aid to the assessment of women with suspected pre-eclampsia: systematic
review and economic analysis. Health Technol Assess 2016;20 : 1-160.
19. Duhig KE, Seed PT, Myers JE, Bahl R, Bambridge G, Barnfield S,
Ficquet J, Girling JC, Khalil A, Shennan AH, Chappell LC, Hunter RM.
Placental growth factor testing for suspected pre-eclampsia: a
cost-effectiveness analysis. BJOG 2019; 126 : 1390-1398.
20. Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, Levine RJ,
Lim KH, Wenger JB, Thadhani R, Karumanchi SA. Angiogenic factors and the
risk of adverse outcomes in women with suspected preeclampsia.Circulation 2012; 125 : 911-919.
21. Zeisler H, Hund M, Verlohren S. The sFlt-1:PlGF Ratio in Women with
Suspected Preeclampsia. N Engl J Med 2016; 374 :
1785-1786.
22. Cerdeira AS, O’Sullivan J, Ohuma EO, Harrington D, Szafranski P,
Black R, Mackillop L, Impey L, Greenwood C, James T, Smith I,
Papageorghiou AT, Knight M, Vatish M. Randomized Interventional Study on
Prediction of Preeclampsia/Eclampsia in Women With Suspected
Preeclampsia: INSPIRE. Hypertension 2019; 74 : 983-990.
23. McCarthy FP, Gill C, Seed PT, Bramham K, Chappell LC, Shennan AH.
Comparison of three commercially available placental growth factor-based
tests in women with suspected preterm pre-eclampsia: the COMPARE study.Ultrasound Obstet Gynecol 2019; 53 : 62-67.
24. Stepan H, Hund M, Gencay M, Denk B, Dinkel C, Kaminski WE, Wieloch
P, Semus B, Meloth T, Dröge LA, Verlohren S. A comparison of the
diagnostic utility of the sFlt-1/PlGF ratio versus PlGF alone for the
detection of preeclampsia/HELLP syndrome. Hypertens Pregnancy2016; 35 : 295-305.
25. Benton SJ, Hu Y, Xie F, Kupfer K, Lee SW, Magee LA, von Dadelszen P.
Angiogenic factors as diagnostic tests for preeclampsia: a performance
comparison between two commercial immunoassays. Am J Obstet
Gynecol 2011; 205 : 469.e461-468.
26. Cnossen JS, ter Riet G, Mol BW, van der Post JA, Leeflang MM, Meads
CA, Hyde C, Khan KS. Are tests for predicting pre-eclampsia good enough
to make screening viable? A review of reviews and critical appraisal.Acta Obstet Gynecol Scand 2009; 88 : 758-765.
27. Black C, Al-Amin A, Rolnik DL, Kane SC, Stolarek C, White A, da
Silva Costa F, Brennecke S. Midpregnancy testing for soluble fms-like
tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF): An
inter-assay comparison of three automated immunoassay platforms.Placenta 2019; 86 : 11-14.
28. Cheng YKY, Poon LCY, Shennan A, Leung TY, Sahota DS.
Inter-manufacturer comparison of automated immunoassays for the
measurement of soluble FMS-like tyrosine kinase-1 and placental growth
factor. Pregnancy Hypertens 2019; 17 : 165-171.
29. Duhig KE, Webster LM, Sharp A, Gill C, Seed PT, Shennan AH, Myers
JE, Chappell LC. Diagnostic accuracy of repeat placental growth factor
measurements in women with suspected preeclampsia: a case series study.Acta Obstet Gynecol Scand 2020.
30. Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M,
Olovsson M, Brennecke SP, Stepan H, Allegranza D, Schoedl M, Grill S,
Hund M, Verlohren S. Soluble fms-like tyrosine kinase-1 to placental
growth factor ratio: ruling out pre-eclampsia for up to 4 weeks and
value of retesting. Ultrasound Obstet Gynecol 2019; 53 :
367-375.
31. Rana S, Hacker MR, Modest AM, Salahuddin S, Lim KH, Verlohren S,
Perschel FH, Karumanchi SA. Circulating angiogenic factors and risk of
adverse maternal and perinatal outcomes in twin pregnancies with
suspected preeclampsia. Hypertension 2012; 60 : 451-458.
32. Saleh L, Tahitu SIM, Danser AHJ, van den Meiracker AH, Visser W. The
predictive value of the sFlt-1/PlGF ratio on short-term absence of
preeclampsia and maternal and fetal or neonatal complications in twin
pregnancies. Pregnancy Hypertens 2018; 14 : 222-227.
33. Dröge L, Herraìz I, Zeisler H, Schlembach D, Stepan H, Küssel L,
Henrich W, Galindo A, Verlohren S. Maternal serum sFlt-1/PlGF ratio in
twin pregnancies with and without pre-eclampsia in comparison with
singleton pregnancies. Ultrasound Obstet Gynecol 2015;45 : 286-293.
34. Benton SJ, McCowan LM, Heazell AE, Grynspan D, Hutcheon JA, Senger
C, Burke O, Chan Y, Harding JE, Yockell-Lelièvre J, Hu Y, Chappell LC,
Griffin MJ, Shennan AH, Magee LA, Gruslin A, von Dadelszen P. Placental
growth factor as a marker of fetal growth restriction caused by
placental dysfunction. Placenta 2016; 42 : 1-8.
35. Gaccioli F, Sovio U, Cook E, Hund M, Charnock-Jones DS, Smith GCS.
Screening for fetal growth restriction using ultrasound and the
sFLT1/PlGF ratio in nulliparous women: a prospective cohort study.Lancet Child Adolesc Health 2018; 2 : 569-581.
36. Griffin M, Seed PT, Duckworth S, North R, Myers J, Mackillop L,
Simpson N, Waugh J, Anumba D, Kenny LC, Redman CWG, Shennan AH, Chappell
LC. Predicting delivery of a small-for-gestational-age infant and
adverse perinatal outcome in women with suspected pre-eclampsia.Ultrasound Obstet Gynecol 2018; 51 : 387-395.
37. Griffin M, Seed PT, Webster L, Myers J, MacKillop L, Simpson N,
Anumba D, Khalil A, Denbow M, Sau A, Hinshaw K, von Dadelszen P, Benton
S, Girling J, Redman CW, Chappell LC, Shennan AH. Diagnostic accuracy of
placental growth factor and ultrasound parameters to predict the
small-for-gestational-age infant in women presenting with reduced
symphysis-fundus height. Ultrasound Obstet Gynecol 2015;46 : 182-190.
38. Ukah UV, Mbofana F, Rocha BM, Loquiha O, Mudenyanga C, Usta M, Urso
M, Drebit S, Magee LA, von Dadelszen P. Diagnostic Performance of
Placental Growth Factor in Women With Suspected Preeclampsia Attending
Antenatal Facilities in Maputo, Mozambique. Hypertension 2017;69 : 469-474.
39. Manriquez Rocha B, Mbofana F, Loquiha O, Mudenyanga C, Ukah UV,
Magee LA, von Dadelszen P. Early diagnosis of preeclampsia using
placental growth factor: An operational pilot study in Maputo,
Mozambique. Pregnancy Hypertens 2018; 11 : 26-31.
40. Thadhani R, Hagmann H, Schaarschmidt W, Roth B, Cingoez T,
Karumanchi SA, Wenger J, Lucchesi KJ, Tamez H, Lindner T, Fridman A,
Thome U, Kribs A, Danner M, Hamacher S, Mallmann P, Stepan H, Benzing T.
Removal of Soluble Fms-Like Tyrosine Kinase-1 by Dextran Sulfate
Apheresis in Preeclampsia. J Am Soc Nephrol 2016; 27 :
903-913.
Table 1: Test performance of PlGF-based tests